Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A

As of June 30, 2026, Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 18.84B, placing it among publicly traded companies globally. Its enterprise value stands at 12.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A has 921.33M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 10.03, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A recorded 128.73M in income tax expense.

As of the close on October 23, 2026, Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 39.64% over the past 52 weeks. The 50-day moving average sits at 20.67, while the 200-day moving average is 24.52.

As of June 30, 2026, Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A holds 6.34B in cash and equivalents against 2.15M in total debt, resulting in a net debt position of -3.42B. Total book value stands at 9.21B, with working capital of 6.44B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on June 6, 2019 with a 10:13 split ratio.